Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2025-03-18 AGM Information
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG
AGM Information Classification · 99% confidence The document explicitly states in the title and body: 'Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG'. It details the outcomes of shareholder votes (approving agenda items, re-electing board members) which is the primary function of an AGM results announcement. This directly maps to the AGM Information category.
2025-03-18 English
BRAIN Biotech AG: Michael Schneiders, buy
Director's Dealing Classification · 100% confidence The document explicitly contains the header "Directors’ Dealings" and details a transaction (Acquisition) by a "person discharging managerial responsibilities" (Michael Schneiders, Member of the managing body) involving the company's shares. This directly matches the definition for Director's Dealing (Code: DIRS). The document is a formal notification of insider trading activity.
2025-03-04 English
BRAIN Biotech AG: Michael Schneiders, buy
Director's Dealing Classification · 100% confidence The document explicitly contains the header "Directors’ Dealings" and details a transaction (Acquisition) by a "person discharging managerial responsibilities" (Michael Schneiders, Member of the managing body) involving the company's shares. This directly matches the definition for Director's Dealing (Code: DIRS). The document is a formal notification of insider trading activity.
2025-03-03 English
BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division
Earnings Release Classification · 100% confidence The document explicitly states it is reporting financial figures for the first three months of the fiscal year 2024/25 ("BRAIN Biotech AG has published its financial figures for the first three months of the fiscal year 2024/25"). It contains detailed segment performance data, key financial tables comparing the current 3-month period to the previous year, and an outlook. This structure is characteristic of a comprehensive quarterly or interim financial report, matching the definition for 'Interim / Quarterly Report' (IR). Although it is a press release format, the content is the report itself, not just an announcement of its publication (which would be RPA/RNS). The presence of the term '3M FY 24/25' confirms the interim nature. Q1 2025
2025-02-27 English
Q1 statement / Q1 financial report 2024/2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the period ending 31 December 2024. It contains comprehensive financial data, including a consolidated income statement, balance sheet, cash flow statement, and detailed notes on financial performance and segment reporting. It is not an earnings release (which would be a summary) nor a report publication announcement (as it contains the full financial data). Therefore, it is classified as an Interim/Quarterly Report. Q1 2025
2025-02-27 English
BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division
Earnings Release Classification · 100% confidence The document explicitly states it is reporting financial figures for the first three months of the fiscal year 2024/25 ("BRAIN Biotech AG has published its financial figures for the first three months of the fiscal year 2024/25"). It contains detailed segment performance data, key financial tables comparing the current 3-month period to the previous year, and an outlook. This structure is characteristic of a comprehensive quarterly or interim financial report, matching the definition for 'Interim / Quarterly Report' (IR). Although it is a press release format, the content is the report itself, not just an announcement of its publication (which would be RPA/RNS). The presence of the term '3M FY 24/25' confirms the interim nature. Q1 2025
2025-02-26 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.